NCT00215878

D-serine for Posttraumatic Stress Disorder Treatment

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Herzog Hospital · Academic / Other
• Sex: All
• Age: 25 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to asses the effects of the NMDA receptor full agonist D-serine while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress disorder (PTSD). Dysfunction of neurotransmission mediated at NMDA receptor plays a cardinal role in the pathophysiology of PTSD and PTSD patients typically suffer from cognitive dysfunctions and avoidance\& depressive symptomatology that may be mediated by NMDA receptor function deficits. Thus, enhancement of NMDA activity by using D-serine may be beneficial in the treatment of PTSD. The study design involves two 6 week periods during which the participants will be randomly assigned to receive treatment with D-serine (\~2g /dy)and placebo. This design allows each participant the opportunity to respond to the experimental treatment.

Conditions

• Posttraumatic Stress Disorder

Interventions

Type	Name	Description
DRUG	D-serine (~2g /day)	Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)

Timeline

• Start date: 2003-08-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2005-09-22
• Last updated: 2012-07-09

Locations

1 site across 1 country: Israel